F-1: Innocan Pharma Files F-1 for Nasdaq IPO, Advances CBD Drug

Innocan Pharma Corporation is pursuing a Nasdaq listing and an initial public offering to fund its innovative LPT-CBD drug development for chronic pain and expand its consumer wellness segment.

Summary

• Innocan Pharma operates in two main segments: Pharmaceuticals (developing LPT-CBD for human and animal health) and Consumer Wellness (marketing self-care and beauty products).
• The company is offering 1,538,461 units, each consisting of one common share and one warrant, with an estimated IPO price of $9.75 per unit, based on a proposed 65-for-1 reverse share split.
• LPT-CBD, a synthetic cannabidiol-loaded liposome injection platform, is in late pre-clinical development for chronic pain management, with FDA regulatory review initiated via a successful pre-IND meeting.
• The Consumer Wellness segment, primarily through its B.I. Sky Global Ltd. joint venture (60% owned), focuses on non-CBD personal care and beauty products in the U.S. online market, showing significant revenue growth.
• The company reported a net loss of $229,000 for Q1 2025, a decrease from $1,454,000 in Q1 2024, and an accumulated deficit of $35,490,000 as of March 31, 2025.
• Revenues increased by $1,028,000 to $7,796,000 in Q1 2025, primarily driven by B.I. Sky's online sales, which grew organically by 72.2% and through promotional sales/advertising by 27.8%.
• The company has a patent portfolio of 31 published patents (granted and pending) across eight families, including one granted patent in India for liposomal cannabinoids and uses thereof.

Sentiment

Score: 6

Explanation: The company shows promising pre-clinical progress in its pharmaceutical segment and strong revenue growth in its consumer wellness segment. The IPO is a critical step to secure necessary funding for continued development. However, significant accumulated losses, a 'going concern' qualification, and the inherent high risks and long timelines of drug development temper the overall positive sentiment.

Positives

• Strong revenue growth in the Consumer Wellness segment, with Q1 2025 revenues increasing by $1,028,000 to $7,796,000, primarily from B.I. Sky's online sales.
• LPT-CBD injectable platform shows promise in pre-clinical research for sustained release of synthetic cannabidiol, offering a non-opioid alternative for pain management.
• FDA regulatory review process for LPT-CBD has been initiated with a successful pre-IND meeting, structuring the development plan towards IND submission.
• FDA acknowledged LPT-CBD's potential submission under the 505(b)(2) abbreviated pathway, which could streamline the drug development process by leveraging existing data from approved drugs like Epidiolex.
• Robust intellectual property portfolio with 31 published patents (granted and pending) across eight families, enhancing competitive position.
• Experienced and mission-driven leadership and advisory teams with expertise in business, science, and regulatory affairs.
• Net loss decreased significantly to $229,000 in Q1 2025 from $1,454,000 in Q1 2024, and to $262,000 in 2024 from $4,248,000 in 2023, indicating improved financial performance.
• Working capital increased to $9,812,000 as of March 31, 2025, from $8,474,000 as of December 31, 2024, and $6,207,000 as of December 31, 2023, reflecting improved liquidity.

Negatives

• The company is a pre-clinical stage pharmaceutical company and anticipates significant losses until pharmaceutical products are commercialized.
• Accumulated deficit of $35,490,000 as of March 31, 2025, and a history of net losses since inception in 2018.
• Financial statements contain an explanatory paragraph regarding substantial doubt about the ability to continue as a going concern, which could hinder future financing.
• Expects to need additional funding, which may not be available on acceptable terms or at all, potentially requiring curtailment or discontinuation of product development.
• No revenue has been generated from LPT-CBD product sales in the Pharmaceuticals segment to date.
• Clinical and preclinical development is uncertain, with high risk of failure and potential for substantial delays and increased costs.
• Reliance on third parties for clinical trials, research, and manufacturing introduces risks of unsatisfactory performance or supply interruptions.
• Lack of internal sales, distribution, or marketing experience for pharmaceutical products, requiring significant investment or third-party agreements.

Risks

• We are a pre-clinical stage company and anticipate significant losses until we commercialize our pharmaceutical products.
• We may not achieve or maintain sufficient working capital to meet future obligations.
• We have never generated revenue from LPT CBD product sales in our Pharmaceuticals segment.
• We expect to need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding may require us to curtail, delay, or discontinue operations.
• Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
• Our pharmaceutical product candidates are in preclinical development. We cannot assure that any product candidates will receive regulatory approval, necessary for commercialization.
• We may not receive, or may be delayed in receiving, necessary approvals for our CBD-loaded liposome platform (LPT-CBD) or future products, affecting our ability to grow.
• If the FDAs Section 505(b)(2) pathway for certain of our drug candidates is not available, the development of certain of our drug candidates will likely take significantly longer, cost significantly more and entail significantly greater complexity and risk than currently anticipated, and, in any case may not be successful.
• Legislative or regulatory reforms in the U.S. or EU may make it more difficult and costly to obtain regulatory clearances or approvals, or to manufacture, market, or distribute products after approval.
• Clinical and preclinical development is uncertain. Current pre-clinical programs may experience delays or may never advance to clinical trials, affecting our ability to obtain regulatory approvals or commercialize these programs.
• Future clinical trials may be delayed, certain programs may never advance, or may be more costly, affecting our ability to fund operations and impacting our business.
• Clinical trials may fail to show safety and effectiveness, preventing regulatory approval and commercialization.
• Even with completed preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain, potentially preventing approvals.
• Early-stage clinical trial results may not predict future results; initial data may not reflect final or later-stage trial outcomes.
• Research and development of central nervous system, or CNS, -targeting drugs is difficult, making it hard to predict why a drug works for some patients but not others.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development.
• Product candidates may have side effects or safety risks, delaying or halting development, preventing approval, or limiting commercial potential.
• Approved products may fail to achieve market acceptance, affecting revenue and profitability.
• Clinical trials conducted outside the U.S. may not be accepted by FDA, EMA, or other regulatory authorities.
• Failure to obtain regulatory approval in any jurisdiction could substantially harm our business.
• Complex pharmaceutical product candidates may face manufacturing problems, delaying development or commercialization.
• We may not use expedited development or regulatory review processes for breakthrough or fast track designated products.
• Approved products will face ongoing regulatory obligations and review, incurring additional expenses and potential penalties for non-compliance.
• If the market opportunities for our pharmaceutical product candidates are smaller than we believe, our revenue may be adversely affected. Our ability to identify patients and acquire a significant market share is necessary for profitability and growth.
• The commercial success of any future pharmaceutical products will depend on market acceptance by physicians, healthcare payers, patients, and the medical community.
• If we are unable to establish sales and marketing capabilities or enter agreements with third parties to sell and market any product candidates we develop, we may not successfully commercialize those product candidates.
• We face intense competition and rapid technological change, and our competitors may discover, develop, or commercialize therapies that are similar, more advanced, or more effective than ours.
• The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.
• Failure to comply with controlled substance legislation could restrict or harm our ability to develop and commercialize products.
• Cannabis remains illegal under U.S. federal law, and changes in enforcement priorities could render operations unprofitable or prohibit them.
• The cannabis industry and regulations continue to develop, and changes that differ from our expectations or are adverse to us may impact our business and operations.
• Failure to comply with various regulations could prevent us from carrying on our business and we may incur costs.
• We may become involved in disputes and legal or regulatory proceedings that, if adversely decided or settled, could materially affect our business, financial condition, and results of operations.
• We may be required to recall products and face product liability claims, resulting in unexpected costs and damaging our reputation.
• If our products are not manufactured in compliance with regulations, do not meet quality standards, or result in adverse health effects, it could cause reputational harm, remedial costs, or regulatory enforcement.
• New laws, regulations, enforcement trends, or changes in regulations governing the introduction, marketing, and sale of our products could harm our business.
• Our facilities and those of third-party manufacturers are subject to regulation under the FDCA and FDA regulations.
• Government regulations and private party actions relating to marketing may restrict, our ability to sell products and harm our business, financial condition, and results of operations.
• Government regulation of the Internet and e-commerce is evolving, and unfavorable changes or failure to comply could substantially harm our business, financial condition, and results of operations.
• Healthcare legislation aimed at reducing costs may have a material adverse effect on our business.
• Governments outside the United States may impose strict price controls, adversely affecting our revenues.
• We may seek additional collaborations and may not be successful in maintaining or entering new ones. Even if successful, we may not realize the benefits.
• We rely on third parties for clinical trials, research, and preclinical testing. These third parties may not perform satisfactorily.
• We have no sales, distribution, or marketing experience and may invest significant resources to establish these capabilities. Failure to do so or to enter agreements with third parties may prevent us from generating revenues.
• If we are unable to obtain and maintain effective intellectual property rights, we may not compete effectively.
• We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming, and unsuccessful.
• We need to expand our organization and may have difficulties managing growth, disrupting operations.
• We may not succeed in identifying, discovering, or licensing additional product candidates.
• Employment laws may prevent us from enforcing non-compete covenants, allowing competitors to benefit from former employees expertise.
• Our success depends on retaining executive officers and attracting, retaining, and motivating qualified personnel.
• Increasing scrutiny of sustainability and ESG initiatives could increase costs or impact our business.
• Unfavorable economic and market conditions and financial institution developments may adversely affect our business, operating results, and growth rates.
• We may be classified as a passive foreign investment company, causing adverse tax consequences for U.S. shareholders.
• As a foreign private issuer, we follow home country corporate governance practices and are not subject to certain U.S. securities laws and certain governance requirements such as independent director oversight of the nomination of directors and executive compensation.
• As an emerging growth company, reduced disclosures may make us less attractive to investors.
• Recent initial public offerings (IPOs) of similar companies have experienced extreme volatility unrelated to performance. We may experience similar volatility, affecting the assessment of our shares value.
• Part of our operations are conducted in Israel. Conditions in Israel, including the recent conflict with Iran, attacks by Hamas and other terrorist organizations and Israels war against them, could materially and adversely affect our business.
• It may be difficult to enforce a U.S. judgment against us, our officers, and directors not in the U.S., or to assert U.S. securities laws claims or serve process on our officers and directors not in the U.S.
• We are governed by the corporate laws of Canada which in some cases have a different effect on shareholders than the corporate laws of the United States.
• Our business and operations might be adversely affected by security breaches, including cybersecurity incidents.
• Sales or significant short sales of our common shares, or the perception of such sales, could depress the market price and impair our ability to raise capital.
• If securities or industry analysts do not publish or cease publishing research or reports about us, or if they publish negative reports, our share price and trading volume could decline.

Future Outlook

The company aims to positively impact lives by addressing chronic pain in humans and animals and promoting wellness through innovative products. This involves maintaining a balanced focus across human pharmaceuticals, animal health, and wellness sectors. For human and animal health, the strategy is to continue investing in LPT-CBD injectable technology, progressing towards clinical trials and FDA approval, including submitting an INAD application with the FDA-CVM in H2 2025 for animal health and an IND application for Phase 1a human studies following LPT-CBD scale-up (expected to commence ~3 months post-offering and take ~1 year). A GLP-compliant single-injection preclinical safety study is anticipated within 6-8 months, followed by IND submission. Phase 1a studies are estimated to take 6-8 months and will run in parallel with scientific bridge data collection for a 505(b)(2) application. Phase 1b studies are intended to begin immediately after Phase 1a approval and a repeated-dose GLP safety study. For wellness, the company plans to expand its product portfolio and reach across digital commerce, online channels, and distribution partners, ensuring compliance with regulations like MoCRA. Once key regulatory milestones for LPT-CBD are achieved, the company intends to engage pharmaceutical companies in licensing discussions for non-opioid pain management therapies.

Management Comments

• We are committed to improving quality of life by addressing chronic pain in humans and animals through innovative therapeutic solutions.
• We believe that our proprietary LPT-CBD injectable drug product has demonstrated promise in pre-clinical research for both human and animal use.
• We believe that our robust intellectual property protection will enhance our competitive position and help us establish a strong market presence.
• We believe that progressing along a defined regulatory support and pathways will position us well in the market and on track to commercialization.
• We believe this diversification (across human pharmaceuticals, animal health, and wellness) will help us manage risk, support our potential growth, and broaden our market opportunities and presence.
• We are committed to bringing safer, effective alternatives to the market, transforming the landscape of chronic pain management and wellness.

Industry Context

The company operates within the substantial global pain management market, projected to reach $109 billion by 2032 (4.5% CAGR), driven by rising chronic diseases and the urgent need for non-opioid alternatives due to the opioid crisis. The veterinary pain management market is also growing, estimated at $1.65 billion in 2024 and expected to exceed $2.20 billion by 2029 (5.91% CAGR), fueled by increased pet ownership and awareness of pet health. Additionally, the global beauty and personal care market, valued at $473 billion in 2022, is projected to reach $693 billion by 2031 (4.35% CAGR), with online sales being a fast-growing segment. The company's LPT-CBD technology aims to address the opioid crisis by offering a non-addictive, high-bioavailability, low-side-effect alternative, aligning with FDA's support for non-opioid pain treatments. Its wellness products cater to the growing consumer focus on self-care and health-conscious lifestyles.

Comparison to Industry Standards

• LPT-CBD's demonstrated high bioavailability (approaching 100% in osteoarthritic dogs compared to 6.5%-20% for oral CBD) offers a significant advantage over common CBD delivery methods.
• The company is pursuing the FDA's 505(b)(2) pathway for LPT-CBD, leveraging existing data from approved products like Epidiolex (Jazz Pharmaceuticals), a CBD oral drug approved for epilepsy, which could expedite development compared to a full NDA.
• Competitors in the cannabinoid therapeutic area include Jazz Pharmaceuticals (Epidiolex), AbbVie, Pfizer, Sanofi, Bristol-Myers Squibb (investing in cannabinoid-based therapies), Zynerba Pharmaceuticals (transdermal CBD), Skye Bioscience (synthetic cannabinoid molecules), Corbus Pharmaceuticals Holdings (synthetic cannabinoid for systemic sclerosis), RespireRx Pharmaceutical Inc. (dronabinol for OSA), Synendos Therapeutics AG (endocannabinoid modulators), and Inversago Pharma (peripheral cannabinoid receptor antagonist).
• The company's LPT-CBD aims to differentiate from traditional chronic pain management solutions (opioids, NSAIDs, steroids) by offering a non-addictive, prolonged-release alternative with minimal side effects.
• The FDA's recent approval of Vertex Pharmaceuticals' new class of non-opioid pain medication for acute pain underscores the regulatory commitment to alternatives, potentially favoring Innocan's LPT-CBD development.

Management Changes

Corporate Governance

Related Party Transactions

• Tamar Innovest Limited, a company associated with director Ralph C.L Bossino and the largest shareholder, participated in an August 2023 private placement (17,391 units for $179,400) and a March 2025 debenture unit offering ($1,000,000 gross proceeds).
• The March 2025 debenture and warrants issued to Tamar Innovest Limited are subject to a blocker provision preventing conversion/exercise if it results in ownership exceeding 19.99% of outstanding common shares.
• A founders agreement was signed with Brandzon Co. Ltd. (40% owner of B.I. Sky Global Ltd.) to establish B.I. Sky, with Innocan holding 60%. Roni Kamhi, COO of Innocan, is CEO and co-founding director of B.I. Sky.
• Innocan extended an owner's loan of approximately $3,000,000 to B.I. Sky, bearing interest per Israeli Tax Ordinance, with repayment extended until February 15, 2026, or an exit event.
• A non-interest-bearing personal loan of $14,291 was extended to CEO Iris Bincovich on July 1, 2020, and was fully repaid by December 31, 2023.

Stakeholder Impact

• Shareholders: Potential for dilution from the IPO and future equity raises, but also potential for increased value if LPT-CBD achieves commercial success and the Consumer Wellness segment continues to grow. Subject to Canadian corporate laws which differ from U.S. laws.
• Employees: Success depends on retaining executive officers and attracting/retaining qualified personnel. Employees in Israel may be subject to military reserve duty, potentially disrupting operations.
• Customers: Development of non-opioid pain management therapies aims to improve quality of life for humans and animals. Expansion of wellness products offers more self-care options.
• Investment Professionals: The IPO provides an opportunity to invest in a pharmaceutical tech company with a dual-segment strategy, but with significant risks associated with drug development and early-stage operations.
• Regulatory Authorities: The company is actively engaging with the FDA (human and veterinary) to navigate regulatory pathways for LPT-CBD, demonstrating commitment to compliance.

Next Steps

• Complete LPT-CBD scale-up activities (expected to commence ~3 months post-offering and take ~1 year).
• Conduct a Good Laboratory Practice (GLP)-compliant single-injection preclinical safety study for LPT-CBD (final reporting anticipated within 6-8 months).
• Submit an Investigational New Drug (IND) application to the FDA for the initial Phase 1a study, including clinical protocol and safety report.
• Commence Phase 1a first-in-human study 30 days post-IND submission, assuming acceptable safety results and no clinical hold.
• Collect pharmacokinetic (PK) and exposure data of LPT-CBD during Phase 1a studies to form a scientific bridge to Epidiolex for a 505(b)(2) application (estimated 6-8 months, parallel to Phase 1a).
• Begin Phase 1b studies immediately following approval of Phase 1a results and completion of a repeated-dose GLP safety study.
• Submit an INAD application with the FDA-CVM during the second half of 2025 to commence testing LPT-CBD in the U.S. for animal health.
• Expand the product portfolio and market reach for Consumer Wellness products across digital commerce, online channels, and distribution partners.
• Engage pharmaceutical companies and industry leaders in licensing discussions for LPT-CBD once key regulatory milestones are achieved for human and animal health applications.

Key Dates

Keywords

Innocan Pharma, LPT-CBD, Cannabidiol, Drug Delivery, Chronic Pain Management, Pharmaceuticals, Consumer Wellness, SEC Filing, F-1 Registration, Nasdaq IPO, Pre-clinical Development, FDA Approval, 505(b)(2) Pathway, Intellectual Property, Biotechnology, Animal Health, Beauty Products, Hemp-derived CBD, Corporate Governance, Israel Operations